237 related articles for article (PubMed ID: 33077265)
1. Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
Chen J; Li Y; Zhang J; Zhang M; Wei A; Liu H; Xie Z; Ren W; Duan W; Zhang Z; Shen A; Hu Y
Eur J Med Chem; 2021 Jan; 209():112868. PubMed ID: 33077265
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
[TBL] [Abstract][Full Text] [Related]
3. Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.
Zhang Z; Hou S; Chen H; Ran T; Jiang F; Bian Y; Zhang D; Zhi Y; Wang L; Zhang L; Li H; Zhang Y; Tang W; Lu T; Chen Y
Bioorg Med Chem Lett; 2016 Jun; 26(12):2931-2935. PubMed ID: 27142751
[TBL] [Abstract][Full Text] [Related]
4. Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative.
Zhang J; Chen P; Zhu P; Zheng P; Wang T; Wang L; Xu C; Zhou J; Zhang H
Bioorg Chem; 2020 Jun; 99():103817. PubMed ID: 32361153
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel indole derivatives as potential HDAC/BRD4 dual inhibitors and anti-leukemia agents.
Cheng G; Wang Z; Yang J; Bao Y; Xu Q; Zhao L; Liu D
Bioorg Chem; 2019 Mar; 84():410-417. PubMed ID: 30554080
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Thieno[2,3-
Pan Z; Li X; Wang Y; Jiang Q; Jiang L; Zhang M; Zhang N; Wu F; Liu B; He G
J Med Chem; 2020 Apr; 63(7):3678-3700. PubMed ID: 32153186
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors.
Shao M; He L; Zheng L; Huang L; Zhou Y; Wang T; Chen Y; Shen M; Wang F; Yang Z; Chen L
Bioorg Med Chem Lett; 2017 Sep; 27(17):4051-4055. PubMed ID: 28765013
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of imidazolopyridone derivatives as novel BRD4 inhibitors.
Yang Y; Chen P; Zhao L; Zhang B; Xu C; Zhang H; Zhou J
Bioorg Med Chem; 2021 Jan; 29():115857. PubMed ID: 33191086
[TBL] [Abstract][Full Text] [Related]
11. Discovery of the natural product 3',4',7,8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor.
Li J; Zou W; Yu K; Liu B; Liang W; Wang L; Lu Y; Jiang Z; Wang A; Zhu J
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):903-913. PubMed ID: 33820450
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat.
Chu-Farseeva YY; Mustafa N; Poulsen A; Tan EC; Yen JJY; Chng WJ; Dymock BW
Eur J Med Chem; 2018 Oct; 158():593-619. PubMed ID: 30243158
[TBL] [Abstract][Full Text] [Related]
15. Discovery of pyridone-based histone deacetylase inhibitors: approaches for metabolic stability.
Cho M; Choi E; Yang JS; Lee C; Seo JJ; Kim BS; Oh SJ; Kim HM; Lee K; Park SK; Kwon HJ; Han G
ChemMedChem; 2013 Feb; 8(2):272-9. PubMed ID: 23292995
[TBL] [Abstract][Full Text] [Related]
16. Binding pocket-based design, synthesis and biological evaluation of novel selective BRD4-BD1 inhibitors.
Ma J; Chen H; Yang J; Yu Z; Huang P; Yang H; Zheng B; Liu R; Li Q; Hu G; Chen Z
Bioorg Med Chem; 2019 May; 27(9):1871-1881. PubMed ID: 30926312
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of novel dual BRD4/HDAC inhibitors.
Amemiya S; Yamaguchi T; Hashimoto Y; Noguchi-Yachide T
Bioorg Med Chem; 2017 Jul; 25(14):3677-3684. PubMed ID: 28549889
[TBL] [Abstract][Full Text] [Related]
18. Exploration of certain 1,3-oxazole- and 1,3-thiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
Anh DT; Hai PT; Huong LT; Park EJ; Jun HW; Kang JS; Kwon JH; Dung DTM; Anh VT; Hue VTM; Han SB; Nam NH
Bioorg Chem; 2020 Aug; 101():103988. PubMed ID: 32534346
[TBL] [Abstract][Full Text] [Related]
19. Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery.
Liang D; Yu Y; Ma Z
Eur J Med Chem; 2020 Aug; 200():112426. PubMed ID: 32502863
[TBL] [Abstract][Full Text] [Related]
20. Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
Dong G; Chen W; Wang X; Yang X; Xu T; Wang P; Zhang W; Rao Y; Miao C; Sheng C
J Med Chem; 2017 Oct; 60(19):7965-7983. PubMed ID: 28885834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
